Search Results - "Burmester, Gerd-Rüdiger"

Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany.

Authors: Krüger, Klaus Burmester, Gerd Rüdiger Wassenberg, Siegfried et al.

Source: Rheumatology & Therapy. Jun2020, Vol. 7 Issue 2, p371-382. 12p.

This result is not displayed to guests.
Login for full access.

Golimumab improves socio economic and health economic parameters in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Authors: Krüger, Klaus Burmester, Gerd Rüdiger Wassenberg, Siegfried et al.

Source: Current Medical Research & Opinion. Sep2020, Vol. 36 Issue 9, p1559-1567. 9p.

Optimised glucocorticoid therapy: the sharpening of an old spear.

Authors: Buttgereit, Frank Burmester, Gerd-Rüdiger Lipworth, Brian J.

Source: Lancet. 2/26/2005, Vol. 365 Issue 9461, p801-803. 3p. 2 Diagrams.

Subjects: Glucocorticoids, Adrenocortical hormones, Anti-inflammatory agents, Drug side effects, Pediatric therapy

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.

Authors: Smolen, Josef S. Burmester, Gerd-Rüdiger Combe, Bernard et al.

Source: Lancet. 12/3/2016, Vol. 388 Issue 10061, p2763-2774. 12p. 1 Diagram, 2 Charts, 4 Graphs.

Subjects: Rheumatoid arthritis treatment, Antirheumatic agents, Adalimumab, Tumor necrosis factors, Treatment effectiveness, Medication safety, Therapeutics, Methotrexate, Comparative studies, Research methodology, Medical cooperation, Monoclonal antibodies, Research, Rheumatoid arthritis, Evaluation research, Randomized controlled trials, Blind experiment

The proteasome — victim or culprit in autoimmunity.

Authors: Feist, Eugen Burmester, Gerd-Rüdiger Krüger, Elke

Source: Clinical Immunology. Nov2016, Vol. 172, p83-89. 7p.

The Safety of Antirheumatic Drugs.

Authors: Mucke, Johanna Simon, Hans-Uwe Burmester, Gerd Rüdiger

Source: Deutsches Ärzteblatt International. 2/11/2022, Vol. 119 Issue 6, p81-87. 12p.

Exogenous and endogenous glucocorticoids in rheumatic diseases.

Authors: Buttgereit, Frank Burmester, Gerd-Rüdiger Straub, Rainer H. et al.

Source: Arthritis & Rheumatism. Jan2011, Vol. 63 Issue 1, p1-9. 9p.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Listening to patients, for the patients: The COVAD Study—Vision, organizational structure, and challenges.

Authors: Joshi, Mrudula Darooka, Naitica Saha, Sreoshy et al.

Source: International Journal of Rheumatic Diseases. May2024, Vol. 27 Issue 5, p1-9. 9p.

Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis.

Authors: Curtis, Jeffrey R. Emery, Paul Downie, Bryan et al.

Source: Rheumatology & Therapy. Feb2024, Vol. 11 Issue 1, p177-189. 13p.

Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.

Authors: Avci, Ali Berkant Feist, Eugen Burmester, Gerd Rüdiger

Source: Rheumatology. 2021 Supplement, Vol. 60, pii11-ii16. 6p.

SIGLEC-1 in Systemic Sclerosis: A Useful Biomarker for Differential Diagnosis.

Authors: Höppner, Jakob Casteleyn, Vincent Biesen, Robert et al.

Source: Pharmaceuticals (14248247). Oct2022, Vol. 15 Issue 10, p1198-N.PAG. 13p.

Unusual Differential Diagnosis in Suspected Meningitis.

Authors: Dittert, Philipp Hermann, Kay Geert Burmester, Gerd Rüdiger

Source: Deutsches Ärzteblatt International. 1/28/2022, Vol. 119 Issue 4, p58-58. 2/3p.

Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?

Authors: Avci, Ali Berkant Feist, Eugen Burmester, Gerd Rüdiger

Source: BioDrugs. Dec2018, Vol. 32 Issue 6, p531-546. 16p.

Une journée dans la vie d'un rhumatologue en 2030.

Authors: Krusche, Martin Mucke, Johanna Burmester, Gerd-Rüdiger

Source: Revue du Rhumatisme. May2021, Vol. 88 Issue 3, p163-165. 3p.

What will be the job of the rheumatologist in 2030?

Authors: Krusche, Martin Mucke, Johanna Burmester, Gerd-Rüdiger

Source: Joint Bone Spine. Dec2020, Vol. 87 Issue 6, p525-527. 3p.

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.

Authors: Weinblatt, Michael E. Bingham, Clifton O. Burmester, Gerd‐Rüdiger et al.

Source: Arthritis & Rheumatology. Oct2017, Vol. 69 Issue 10, p1937-1948. 12p.

Osteoarthritis synovial fluid activates pro-inflammatory cytokines in primary human chondrocytes.

Authors: Hoff, Paula Buttgereit, Frank Burmester, Gerd-Rüdiger et al.

Source: International Orthopaedics. Jan2013, Vol. 37 Issue 1, p145-151. 7p.